8-K: KORU Medical Reports Strong 2025 Growth, Positive Adjusted EBITDA

KORU Medical Systems announced robust fourth quarter and full year 2025 financial results, achieving significant revenue growth and positive adjusted EBITDA, while initiating optimistic 2026 guidance.

Summary

• Fourth quarter 2025 net revenues increased 23% to $10.9 million.
• Full year 2025 net revenues grew 22% to $41.1 million.
• Full year 2025 gross profit rose 20% to $25.6 million, with a gross margin of 62.3%.
• Net loss for full year 2025 improved by 57% to ($2.6) million, compared to ($6.1) million in the prior year.
• Adjusted EBITDA for full year 2025 turned positive at $0.6 million, a 124% increase from ($2.5) million in 2024.
• Ending cash balance as of December 31, 2025, was $8.9 million, with annual cash usage improving by 63% to $0.7 million.
• Received 510(k) clearance for UCB RYSTIGGO, expanding the platform beyond Ig into broader therapeutic indications.
• Announced Freedom60 EU MDR certification with prefilled syringe compatibility.
• Expanded development pipeline with two new pharmaceutical collaborations, including a Phase III nephrology molecule and a multi-indication drug in a Phase I trial.
• Initiated 2026 guidance projecting net revenues of $47.5 $50.0 million (15% 22% growth), gross margin of 61% 63%, positive adjusted EBITDA, and positive cash flow for the full year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, a significant improvement in net loss, the achievement of positive adjusted EBITDA, and optimistic 2026 guidance, indicating a strong operational turnaround and future potential.

Positives

• Strong revenue growth: 23% in Q4 2025 and 22% for the full year 2025, driven by domestic and international core market expansion.
• Significant improvement in profitability: Full year 2025 net loss improved by 57% to ($2.6) million, and adjusted EBITDA turned positive at $0.6 million from a ($2.5) million loss in 2024.
• Improved cash management: Annual cash usage decreased by 63% to $0.7 million, contributing to a stable ending cash balance of $8.9 million.
• Strategic product advancements: Achieved 510(k) clearance for UCB RYSTIGGO and Freedom60 EU MDR certification, broadening market reach and product capabilities.
• Expanded R&D pipeline: Secured two new pharmaceutical collaborations for a Phase III nephrology molecule and a multi-indication drug in Phase I, indicating future growth potential.
• Optimistic 2026 guidance: Forecasts continued revenue growth (15%-22%), stable gross margins, and sustained positive adjusted EBITDA and cash flow.

Negatives

• Despite significant improvement, the company still reported a GAAP net loss of ($2.6) million for the full year 2025.
• Full year 2025 gross margin slightly decreased to 62.3% from 63.4% in 2024, primarily due to higher material costs, tariff-related charges, and geographic sales mix.
• Pharma Services and Clinical Trials (PST) net revenues decreased by 30.1% in Q4 2025 and 5.6% for the full year 2025, mainly due to the timing of NRE collaboration project milestones.

Risks

• Uncertainties associated with SCIg market growth.
• Risks related to prefilled syringe penetration.
• Dependence on plasma supply.
• Uncertainties regarding clinical trial activity and success.
• Risks associated with the approval and commercialization of new drug indications.
• Impact of the shift to increased healthcare delivery in the home.
• Variability in new patient diagnoses and customer ordering patterns.
• Exposure to global and regional instability.
• Challenges from innovation and competition.
• Potential for labor and supply price increases.
• Impacts of inflationary pressures.
• Availability and cost of labor supply.

Future Outlook

KORU Medical Systems expects full year 2026 net revenues to be between $47.5 million and $50.0 million, representing growth of 15% to 22%. The company also anticipates a full year 2026 gross margin between 61% and 63%, along with positive adjusted EBITDA and positive cash flow for the full year.

Management Comments

• Linda Tharby, President and CEO, stated, 'Our fourth quarter and full year performance reflect the meaningful progress we have made building a stronger, more scalable business positioned to meet the evolving needs of the subcutaneous infusion market.'
• Linda Tharby also noted, 'Demand for immunoglobulin therapy remains robust, supporting continued growth in our recurring patient base, and we continue to gain momentum with International Core expansion.'
• Linda Tharby further commented, 'Our 510(k) filings and clearances are broadening our platform beyond Ig and into new therapeutic areas, further expanding our patient base.'
• Linda Tharby concluded, 'We enter 2026 with a proven ability to execute on our strategy, a compelling set of additional growth opportunities, and a continued commitment to shareholder value generation.'

Industry Context

StockSavvy.ai notes that KORU Medical's strong performance aligns with broader trends favoring home-based healthcare solutions and specialized infusion therapies. The expansion into new therapeutic areas beyond immunoglobulin (Ig) with clearances like UCB RYSTIGGO positions the company to capitalize on the growing demand for patient-centric, large-volume subcutaneous infusion solutions, a market segment experiencing robust growth.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess KORU Medical's performance against global industry benchmarks. Therefore, a direct comparison to industry standards based solely on this filing is not feasible.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong financial performance, positive adjusted EBITDA, and optimistic future guidance.
• Patients: Expanded platform and new therapeutic indications (e.g., UCB RYSTIGGO) could lead to improved quality of life through innovative subcutaneous infusion solutions.
• Employees: Continued growth and strategic expansion may lead to job stability and potential opportunities.
• Customers (healthcare professionals/biopharmaceutical companies): New product certifications (EU MDR) and expanded development collaborations offer enhanced solutions and partnership opportunities.

Next Steps

• KORU Medical Systems will host a live conference call and webcast on March 12, 2026, at 4:30 PM ET to discuss these results and provide a corporate update.
• Continue to execute on strategy to meet evolving needs of the subcutaneous infusion market.
• Further expand the platform beyond Ig into new therapeutic areas following 510(k) clearances.
• Advance the expanded development pipeline, including a Phase III nephrology molecule and a multi-indication drug in a Phase I trial.

Key Dates

Recommendation

Based on the filing, KORU Medical Systems demonstrates a strong operational turnaround with significant revenue growth, a shift to positive adjusted EBITDA, and a clear path to positive cash flow in 2026. Strategic advancements like new 510(k) clearances and an expanded development pipeline further bolster future growth prospects. While a GAAP net loss persists, the substantial improvement and positive guidance suggest a compelling investment opportunity for a seasoned investor looking for a company with strong momentum in a growing market segment.

Keywords

Medical Technology, Subcutaneous Infusion, SCIg, Adjusted EBITDA, Financial Results, 2026 Guidance, 510(k) Clearance, EU MDR Certification, Pharmaceutical Collaborations, Home Healthcare